Given its more selective effect on GR and the better safety profile as compared with mifepristone and the promising results with this latter drug in patients with mHC, relacorilant represents an interesting possibility for patients affected with mHC and hypertension or glucose metabolism impairment. Here, NR3C1 is linked to Hypertension.